Exact Sciences
Biotechnologieforschung
Madison, Wisconsin 109.339 Follower:innen
Changing the way we think about detecting and treating cancer.
Putting an end to cancer
Cancer takes things from people — time, comfort, sometimes lives. At Exact Sciences, we bring together the best in visionary thinking and scientific rigor for a single purpose: to help eradicate cancer. Our tests help identify cancer risk, detect cancer earlier when it’s more treatable, and understand each cancer’s unique DNA, to help those diagnosed find their best path forward. Today, we’re building the next wave of breakthroughs, to give everyone more time for the moments that matter.
Explore our testsEarlier is everything
A great way to fight cancer: get ahead of it. Colorectal cancer is the third most commonly occurring cancer in men and women, according to the American Cancer Society. Our flagship product, Cologuard®, is an FDA-approved, noninvasive stool-based DNA test that has been used by millions to screen for colorectal cancer at home. Our Riskguard™ Hereditary Cancer Test helps a person understand their risk of developing inherited forms of cancer and their options for screening.
Insights tailored to every patient
Each patient is unique. Each cancer is, too. So a one-size-fits-all approach to treatment won’t do. Our Precision Oncology portfolio of genomic tests delivers insights based on individualized tumor biology, helping patients and healthcare professionals make treatment decisions with confidence.
Firmenfotos
Verbundene Seiten
Ähnliche Seiten
Aktien
EXAS
NASDAQ
Verzögerung von 20 Minuten
59,84 $
0,725 (1,227 %)
- Aktiv
- 58,59
- Niedrig
- 58,57
- Hoch
- 59,92
Daten von Refinitiv
Mehr Informationen auf